Krystal Biotech (NASDAQ:KRYS) Now Covered by Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $245.00 target price on the stock.

Several other brokerages have also recently commented on KRYS. Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup lifted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $220.00.

Krystal Biotech Stock Performance

KRYS opened at $180.06 on Wednesday. The stock has a market capitalization of $5.19 billion, a price-to-earnings ratio of 60.22 and a beta of 0.87. Krystal Biotech has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The company has a fifty day moving average of $160.40 and a 200 day moving average of $174.84.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.30 EPS. On average, equities research analysts forecast that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. New York State Teachers Retirement System grew its holdings in shares of Krystal Biotech by 6.6% in the third quarter. New York State Teachers Retirement System now owns 15,879 shares of the company’s stock worth $2,890,000 after purchasing an additional 979 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Krystal Biotech by 17.1% in the third quarter. Janney Montgomery Scott LLC now owns 37,047 shares of the company’s stock worth $6,744,000 after purchasing an additional 5,415 shares during the last quarter. TimesSquare Capital Management LLC grew its holdings in shares of Krystal Biotech by 37.6% in the third quarter. TimesSquare Capital Management LLC now owns 114,222 shares of the company’s stock worth $20,792,000 after purchasing an additional 31,183 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Krystal Biotech by 25.8% in the third quarter. Crossmark Global Holdings Inc. now owns 2,186 shares of the company’s stock worth $398,000 after purchasing an additional 449 shares during the last quarter. Finally, Prime Capital Investment Advisors LLC grew its holdings in shares of Krystal Biotech by 93.1% in the third quarter. Prime Capital Investment Advisors LLC now owns 2,591 shares of the company’s stock worth $472,000 after purchasing an additional 1,249 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).